Industries > Pharma > Retinal Disorder Treatment Market Report 2021-2031
Retinal Disorder Treatment Market Report 2021-2031
By Disease Indication (Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Retinal Vein Occlusion, and Others), By Therapeutic Class (Anti-VEGF Agents, Anti-inflammatory Drugs, and Others), By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments, and Others), By Patient Demographics (Adults, Geriatric, and Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) and Leading Regional/ Country market analysis
Retinal Disorder Treatment Market– our new study reveals trends, R&D progress, and predicted revenues
Where the Retinal Disorder Treatment is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our 250+ page report provides 410+ tables and 390+ charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Retinal Disorder Treatment Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
• Revenue and growth forecasts from 2021 to 2031 for the Global Retinal Disorder Treatment Market By Disease Indication
• Macular Degeneration
o Dry Macular Degeneration
o Wet Macular Degeneration
• Diabetic Retinopathy
• Diabetic Macular Edema
• Retinal Vein Occlusion
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Retinal Disorder Treatment Market By Therapeutic Class
• Anti-VEGF Agents
• Anti-inflammatory Drugs
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Retinal Disorder Treatment Market By Dosage Form
• Gels
• Eye Solutions
• Capsules & Tablets
• Eye Drops
• Ointments
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Retinal Disorder Treatment Market By Patient Demographics
• Adults
• Geriatric
• Pediatric
• Revenue and growth forecasts from 2021 to 2031 for the Global Retinal Disorder Treatment Market By End User
• Hospitals
• Homecare
• Specialty Clinics
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Retinal Disorder Treatment Market By Distribution Channel
• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Retinal Disorder Treatment Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Retinal Disorder Treatment Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Retinal Disorder Treatment Market report helps you
In summary, our 250+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Retinal Disorder Treatment Market, with forecasts for Get our report today Retinal Disorder Treatment Market Forecast 2021-2031: By Disease Indication, Therapeutic Class, Dosage Form, Patient Demographics, End User, Distribution Channel and Leading Regional/ Country market analysis each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Retinal Disorder Treatment market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Retinal Disorder Treatment Market. Some of the company’s profiled in this report include
• Santen Pharmaceutical Co., Ltd.
• Regeneron Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• Allergan plc
• Shire (Takeda Pharmaceutical Company Limited)
• Bayer AG
• Graybug Vision, Inc.
• Novartis AG
• Acucela Inc. (Kubota Pharmaceutical Holdings Co., Ltd.).
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Retinal Disorder Treatment Market and leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Retinal Disorder Treatment Market Report 2021-2031: By Disease Indication (Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Retinal Vein Occlusion, and Others), By Therapeutic Class (Anti-VEGF Agents, Anti-inflammatory Drugs, and Others), By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments, and Others), By Patient Demographics (Adults, Geriatric, and Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) and Leading Regional/ Country market analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Retinal Disorder Treatment Market
2.1. Retinal Disorder Treatment Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Retinal Disorder Treatment Market Overview
3.1. Global Retinal Disorder Treatment Market Size and Forecast By Region
3.2. Global Retinal Disorder Treatment Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing Geriatric Population around the World
3.3.1.2. Increasing Prevalence of Retinal Disorders
3.3.1.3. Rapid change in lifestyle
3.3.1.4. Increasing research and developments
3.3.2. Market Restraints
3.3.2.1. Stringent Regulation associated with product development
3.3.2.2. High Cost of development
3.3.3. Opportunities
3.3.3.1. Increasing Strategic initiatives in retinal disorders treatment Drugs
3.3.3.2. Growing regulatory approvals
3.3.4. Challenges
3.3.4.1. Availability of alternative methods
3.3.4.2. Product recalls
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Retinal Disorder Treatment Market Analysis and Forecast 2021-2031, By Disease Indication (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Macular Degeneration
4.1.1.1. Macular Degeneration market size and forecast, 2021-2031 (USD Million)
4.1.2. Diabetic Retinopathy
4.1.2.1. Diabetic Retinopathy market size and forecast, 2021-2031 (USD Million)
4.1.3. Diabetic Macular Edema
4.1.3.1. Diabetic Macular Edema market size and forecast, 2021-2031 (USD Million)
4.1.4. Retinal Vein Occlusion
4.1.4.1. Retinal Vein Occlusion market size and forecast, 2021-2031 (USD Million)
4.1.5. Others
4.1.5.1. Others market size and forecast, 2021-2031 (USD Million)
5. Global Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 By Dosage Form (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Gels
5.1.1.1. Gels market size and forecast, 2021-2031 (USD Million)
5.1.2. Eye Solutions
5.1.2.1. Eye Solutions market size and forecast, 2021-2031 (USD Million)
5.1.3. Capsules & Tablets
5.1.3.1. Capsules & Tablets market size and forecast, 2021-2031 (USD Million)
5.1.4. Eye Drops
5.1.4.1. Eye Drops market size and forecast, 2021-2031 (USD Million)
5.1.5. Ointments
5.1.5.1. Ointments market size and forecast, 2021-2031 (USD Million)
5.1.6. Others
5.1.6.1. Others market size and forecast, 2021-2031 (USD Million)
6. Global Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Geriatric
6.1.1.1. Geriatric market size and forecast, 2021-2031 (USD Million)
6.1.2. Adult
6.1.2.1. Adult market size and forecast, 2021-2031 (USD Million)
6.1.3. Pediatric
6.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
7. Global Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 By Therapeutic Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Anti-VEGF Agents
7.1.1.1. Anti-VEGF Agents market size and forecast, 2021-2031 (USD Million)
7.1.2. Anti-inflammatory Drugs
7.1.2.1. Anti-inflammatory Drugs market size and forecast, 2021-2031 (USD Million)
7.1.3. Others
7.1.3.1. Others market size and forecast, 2021-2031 (USD Million)
8. Global Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Hospitals
8.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
8.1.2. Homecare
8.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
8.1.3. Specialty Clinics
8.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
8.1.4. Others
8.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
9. Global Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospitals Pharmacy
9.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
9.1.2. Retail Pharmacy
9.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
9.1.3. Online Pharmacies
9.1.3.1. Online Pharmacies market size and forecast, 2021-2031 (USD Million)
10. North America Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. North America Retinal Disorder Treatment Market Size and Forecast By Disease Indication
10.2.1.1. XX Driving/Opportunity Factor
10.2.1.2. XX Driving/Opportunity Factor
10.3. North America Retinal Disorder Treatment Market Size and Forecast By Dosage Form
10.3.1.1. XX Driving/Opportunity Factor
10.3.1.2. XX Driving/Opportunity Factor
10.4. North America Retinal Disorder Treatment Market Size and Forecast By Therapeutic Class
10.4.1.1. XX Driving/Opportunity Factor
10.4.1.2. XX Driving/Opportunity Factor
10.5. North America Retinal Disorder Treatment Market Size and Forecast By Patient Demographics
10.5.1.1. XX Driving/Opportunity Factor
10.5.1.2. XX Driving/Opportunity Factor
10.6. North America Retinal Disorder Treatment Market Size and Forecast By End-User
10.6.1.1. XX Driving/Opportunity Factor
10.6.1.2. XX Driving/Opportunity Factor
10.7. North America Retinal Disorder Treatment Market Size and Forecast By Distribution Channel
10.7.1.1. XX Driving/Opportunity Factor
10.7.1.2. XX Driving/Opportunity Factor
10.8. U.S. Retinal Disorder Treatment Market
10.8.1.1. XX Driving/Opportunity Factor
10.8.1.2. XX Driving/Opportunity Factor
10.9. Canada Retinal Disorder Treatment Market
10.9.1.1. XX Driving/Opportunity Factor
10.9.1.2. XX Driving/Opportunity Factor
11. Europe Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Europe Retinal Disorder Treatment Market Size and Forecast By Disease Indication
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. Europe Retinal Disorder Treatment Market Size and Forecast By Dosage Form
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. Europe Retinal Disorder Treatment Market Size and Forecast By Patient Demographics
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. Europe Retinal Disorder Treatment Market Size and Forecast By Therapeutic Class
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. Europe Retinal Disorder Treatment Market Size and Forecast By End-User
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. Europe Retinal Disorder Treatment Market Size and Forecast By Distribution Channel
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. UK Retinal Disorder Treatment Market
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. Germany Retinal Disorder Treatment Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. France Retinal Disorder Treatment Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
11.11. Rest of Europe Retinal Disorder Treatment Market
11.11.1.1. XX Driving/Opportunity Factor
11.11.1.2. XX Driving/Opportunity Factor
12. Asia Pacific Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Asia-Pacific Retinal Disorder Treatment Market Size and Forecast By Disease Indication
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Asia-Pacific Retinal Disorder Treatment Market Size and Forecast By Dosage Form
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Asia-Pacific Retinal Disorder Treatment Market Size and Forecast By Patient Demographics
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Asia-Pacific Retinal Disorder Treatment Market Size and Forecast By Therapeutic Class
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Asia-Pacific Retinal Disorder Treatment Market Size and Forecast By End-User
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Asia-Pacific Retinal Disorder Treatment Market Size and Forecast By Distribution Channel
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. China Retinal Disorder Treatment Market
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. India Retinal Disorder Treatment Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Japan Retinal Disorder Treatment Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. Rest of Asia Pacific Retinal Disorder Treatment Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
13. Latin America Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Latin America Retinal Disorder Treatment Market Size and Forecast By Disease Indication
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Latin America Retinal Disorder Treatment Market Size and Forecast By Dosage Form
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Latin America Retinal Disorder Treatment Market Size and Forecast By Patient Demographics
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Latin America Retinal Disorder Treatment Market Size and Forecast By Therapeutic Class
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Latin America Retinal Disorder Treatment Market Size and Forecast By End-User
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Latin America Retinal Disorder Treatment Market Size and Forecast By Distribution Channel
13.8. Brazil Retinal Disorder Treatment Market
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Mexico Retinal Disorder Treatment Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. Rest of Latin America Retinal Disorder Treatment Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
14. MEA Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. MEA Retinal Disorder Treatment Market Size and Forecast By Disease Indication
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. MEA Retinal Disorder Treatment Market Size and Forecast By Dosage Form
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. MEA Retinal Disorder Treatment Market Size and Forecast By Patient Demographics
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. MEA Retinal Disorder Treatment Market Size and Forecast By Therapeutic Class
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. MEA Retinal Disorder Treatment Market Size and Forecast By End-User
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. MEA Retinal Disorder Treatment Market Size and Forecast By Distribution Channel
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. GCC Retinal Disorder Treatment Market
14.8.1.1. XX Driving/Opportunity Factor
14.8.1.2. XX Driving/Opportunity Factor
14.9. South Africa Retinal Disorder Treatment Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Rest of MEA Retinal Disorder Treatment Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
15. Companies in the Retinal Disorder Treatment Market
15.1. Santen Pharmaceutical Co., Ltd.
15.1.1. Company Snapshot
15.1.2. Company Overview
15.1.3. Financial Performance (2015-2019)
15.1.3.1. Net Revenue
15.1.3.2. Gross Profit
15.1.3.3. Geographical Revenue, 2019
15.1.4. Product Offerings
15.1.5. Recent Initiatives (2017-2019)
15.2. Regeneron Pharmaceuticals, Inc.
15.2.1. Company Snapshot
15.2.2. Company Overview
15.2.3. Financial Performance (2015-2019)
15.2.3.1. Net Revenue
15.2.3.2. Gross Profit
15.2.3.3. Geographical Revenue, 2019
15.2.4. Product Offerings
15.2.5. Recent Initiatives (2017-2019)
15.3. F. Hoffmann-La Roche Ltd.
15.3.1. Company Snapshot
15.3.2. Company Overview
15.3.3. Financial Performance (2015-2019)
15.3.3.1. Net Revenue
15.3.3.2. Gross Profit
15.3.3.3. Geographical Revenue, 2019
15.3.4. Product Offerings
15.3.5. Recent Initiatives (2017-2019)
15.4. Pfizer, Inc.
15.4.1. Company Snapshot
15.4.2. Company Overview
15.4.3. Financial Performance (2015-2019)
15.4.3.1. Net Revenue
15.4.3.2. Gross Profit
15.4.3.3. Geographical Revenue, 2019
15.4.4. Product Offerings
15.4.5. Recent Initiatives (2017-2019)
15.5. ALLERGAN PLC
15.5.1. Company Snapshot
15.5.2. Company Overview
15.5.3. Financial Performance (2015-2019)
15.5.3.1. Net Revenue
15.5.3.2. Gross Profit
15.5.3.3. Geographical Revenue, 2019
15.5.4. Product Offerings
15.5.5. Recent Initiatives (2017-2019)
15.6. Shire (Takeda Pharmaceutical Company Limited)
15.6.1. Company Snapshot
15.6.2. Company Overview
15.6.3. Financial Performance (2015-2019)
15.6.3.1. Net Revenue
15.6.3.2. Gross Profit
15.6.3.3. Geographical Revenue, 2019
15.6.4. Product Offerings
15.6.5. Recent Initiatives (2017-2019)
15.7. Bayer AG
15.7.1. Company Snapshot
15.7.2. Company Overview
15.7.3. Financial Performance (2015-2019)
15.7.3.1. Net Revenue
15.7.3.2. Gross Profit
15.7.3.3. Geographical Revenue, 2019
15.7.4. Product Offerings
15.7.5. Recent Initiatives (2017-2019)
15.8. Graybug Vision, Inc.
15.8.1. Company Snapshot
15.8.2. Company Overview
15.8.3. Financial Performance (2015-2019)
15.8.3.1. Net Revenue
15.8.3.2. Gross Profit
15.8.3.3. Geographical Revenue, 2019
15.8.4. Product Offerings
15.8.5. Recent Initiatives (2017-2019)
15.9. Novartis AG
15.9.1. Company Snapshot
15.9.2. Company Overview
15.9.3. Financial Performance (2015-2019)
15.9.3.1. Net Revenue
15.9.3.2. Gross Profit
15.9.3.3. Geographical Revenue, 2019
15.9.4. Product Offerings
15.9.5. Recent Initiatives (2017-2019)
15.10. Acucela Inc. (Kubota Pharmaceutical Holdings Co., Ltd.).
15.10.1. Company Snapshot
15.10.2. Company Overview
15.10.3. Financial Performance (2015-2019)
15.10.3.1. Net Revenue
15.10.3.2. Gross Profit
15.10.3.3. Geographical Revenue, 2019
15.10.4. Product Offerings
15.10.5. Recent Initiatives (2017-2019)
15.11. Other Notable Players
16. Conclusion
17. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Retinal Disorder Treatment Market Drivers & Restraints 2021
Table 7. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 198. Europe Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. Europe Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. Europe Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. Europe Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 242. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 243. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 244. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 245. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 246. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 247. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 248. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 249. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 250. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 251. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 252. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 253. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 254. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 255. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 256. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 257. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 258. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 259. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 260. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 261. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 262. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 367. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 368. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 369. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 370. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 371. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 372. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 373. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 374. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 375. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 376. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 377. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 378. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 379. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 380. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 381. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 382. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 383. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 384. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 385. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 386. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 387. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 388. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 389. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 390. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 391. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 392. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 393. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 394. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 395. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 396. Leading 10 Retinal Disorder Treatment Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 397. Santen Pharmaceutical Co., Ltd.Profile 2019 (CEO, HQ, Founded, Website)
Table 398. Santen Pharmaceutical Co., Ltd. Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 399. Regeneron Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 400. Regeneron Pharmaceuticals, Inc. Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 401. F. Hoffmann-La Roche Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 402. F. Hoffmann-La Roche Ltd..Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 403. Pfizer, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 404. Pfizer, Inc. Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 405. ALLERGAN PLC Profile 2019 (CEO, HQ, Founded, Website)
Table 406. ALLERGAN PLC Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 407. Shire (Takeda Pharmaceutical Company Limited) Profile 2019 (CEO, HQ, Founded, Website)
Table 408. Shire (Takeda Pharmaceutical Company Limited) Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 409. Bayer AG Profile 2019 (CEO, HQ, Founded, Website)
Table 410. Bayer AG Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 411. Graybug Vision, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 412. Graybug Vision, Inc. Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 413. Novartis AG Profile 2019 (CEO, HQ, Founded, Website)
Table 414. Novartis AG Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 415. Acucela Inc. (Kubota Pharmaceutical Holdings Co., Ltd.). Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 416. Acucela Inc. (Kubota Pharmaceutical Holdings Co., Ltd.). Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 417. Other Companies Involved in the Retinal Disorder Treatment Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Retinal Disorder Treatment Market Drivers & Restraints 2021
Figure 7. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 153. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 158. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 163. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 168. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 173. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 183. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 188. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 198. Europe Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. Europe Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. Europe Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. Europe Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 203. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 218. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 223. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 228. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 229. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 230. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 231. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 232. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 233. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 234. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 235. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 236. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 237. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 238. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 239. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 240. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 241. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 242. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 243. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 244. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 245. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 246. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 247. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 248. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 249. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 250. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 251. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 252. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 253. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 254. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 255. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 256. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 257. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 258. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 259. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 260. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 261. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 262. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 367. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 368. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 369. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 370. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 371. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 372. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 373. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 374. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 375. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 376. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 377. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 378. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 379. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 380. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 381. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 382. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 383. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 384. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 385. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 386. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 387. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 388. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 389. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 390. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 391. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 392. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 393. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 394. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 395. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 396. Porter’s Five Force Analysis
Companies Mentioned
1. GlaxoSmithKline PLC
2. Biomarin Pharmaceutical Inc
3. Grifols SA
4. UCB SA
5. Eisai Co Ltd
6. Novo Nordisk A/S
7. Alexion Pharmaceuticals Inc
8. Takeda Pharmaceutical Co Ltd
9. Chugai Pharmaceutical Co Ltd
10. Perrigo Company PLC
11. Astellas Pharma Inc
12. Mitsubishi Tanabe Pharma Corp
13. Johnson & Johnson
14. Shanghai Fosun Pharmaceutical Group Co Ltd
15. Jiangsu Hengrui Medicine Co Ltd
16. Allergan plc
17. Shire PLC
18. Kyowa Hakko Kirin Co Ltd
19. Pfizer Inc
20. Taisho Pharmaceutical Holdings Co Ltd
21. MYL.O
22. Zoetis Inc
23. Bristol-Myers Squibb Co
24. Merck & Co Inc
25. AbbVie Inc
26. Jazz Pharmaceuticals PLC
27. Sumitomo Dainippon Pharma Co Ltd
28. AstraZeneca PLC
29. China Grand Automotive Services Co Ltd
30. Daiichi Sankyo Co Ltd
31. Novartis AG
32. Tasly Pharmaceutical Group Co Ltd
33. CSL Ltd
34. Biogen Inc
35. Orion Oyj
36. Bayer AG
37. CSPC Pharmaceutical Group Ltd
38. Sanofi SA
39. Roche Holding AG
40. Ono Pharmaceutical Co Ltd
41. Beijing Tongrentang Co Ltd
42. Kangmei Pharmaceutical Co Ltd
43. Ipsen SA
44. Abbott Laboratories
45. Shionogi & Co Ltd
46. Eli Lilly and Co
47. Recordati Industria Chimica e Farmaceutica SpA
48. Hikma Pharmaceuticals PLC
49. Teva Pharmaceutical Industries Ltd
50. Merck KGaA
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Retinal Disorder Treatment Market
2.1. Retinal Disorder Treatment Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Retinal Disorder Treatment Market Overview
3.1. Global Retinal Disorder Treatment Market Size and Forecast By Region
3.2. Global Retinal Disorder Treatment Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing Geriatric Population around the World
3.3.1.2. Increasing Prevalence of Retinal Disorders
3.3.1.3. Rapid change in lifestyle
3.3.1.4. Increasing research and developments
3.3.2. Market Restraints
3.3.2.1. Stringent Regulation associated with product development
3.3.2.2. High Cost of development
3.3.3. Opportunities
3.3.3.1. Increasing Strategic initiatives in retinal disorders treatment Drugs
3.3.3.2. Growing regulatory approvals
3.3.4. Challenges
3.3.4.1. Availability of alternative methods
3.3.4.2. Product recalls
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Retinal Disorder Treatment Market Analysis and Forecast 2021-2031, By Disease Indication (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Macular Degeneration
4.1.1.1. Macular Degeneration market size and forecast, 2021-2031 (USD Million)
4.1.2. Diabetic Retinopathy
4.1.2.1. Diabetic Retinopathy market size and forecast, 2021-2031 (USD Million)
4.1.3. Diabetic Macular Edema
4.1.3.1. Diabetic Macular Edema market size and forecast, 2021-2031 (USD Million)
4.1.4. Retinal Vein Occlusion
4.1.4.1. Retinal Vein Occlusion market size and forecast, 2021-2031 (USD Million)
4.1.5. Others
4.1.5.1. Others market size and forecast, 2021-2031 (USD Million)
5. Global Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 By Dosage Form (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Gels
5.1.1.1. Gels market size and forecast, 2021-2031 (USD Million)
5.1.2. Eye Solutions
5.1.2.1. Eye Solutions market size and forecast, 2021-2031 (USD Million)
5.1.3. Capsules & Tablets
5.1.3.1. Capsules & Tablets market size and forecast, 2021-2031 (USD Million)
5.1.4. Eye Drops
5.1.4.1. Eye Drops market size and forecast, 2021-2031 (USD Million)
5.1.5. Ointments
5.1.5.1. Ointments market size and forecast, 2021-2031 (USD Million)
5.1.6. Others
5.1.6.1. Others market size and forecast, 2021-2031 (USD Million)
6. Global Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Geriatric
6.1.1.1. Geriatric market size and forecast, 2021-2031 (USD Million)
6.1.2. Adult
6.1.2.1. Adult market size and forecast, 2021-2031 (USD Million)
6.1.3. Pediatric
6.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
7. Global Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 By Therapeutic Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Anti-VEGF Agents
7.1.1.1. Anti-VEGF Agents market size and forecast, 2021-2031 (USD Million)
7.1.2. Anti-inflammatory Drugs
7.1.2.1. Anti-inflammatory Drugs market size and forecast, 2021-2031 (USD Million)
7.1.3. Others
7.1.3.1. Others market size and forecast, 2021-2031 (USD Million)
8. Global Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Hospitals
8.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
8.1.2. Homecare
8.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
8.1.3. Specialty Clinics
8.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
8.1.4. Others
8.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
9. Global Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospitals Pharmacy
9.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
9.1.2. Retail Pharmacy
9.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
9.1.3. Online Pharmacies
9.1.3.1. Online Pharmacies market size and forecast, 2021-2031 (USD Million)
10. North America Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. North America Retinal Disorder Treatment Market Size and Forecast By Disease Indication
10.2.1.1. XX Driving/Opportunity Factor
10.2.1.2. XX Driving/Opportunity Factor
10.3. North America Retinal Disorder Treatment Market Size and Forecast By Dosage Form
10.3.1.1. XX Driving/Opportunity Factor
10.3.1.2. XX Driving/Opportunity Factor
10.4. North America Retinal Disorder Treatment Market Size and Forecast By Therapeutic Class
10.4.1.1. XX Driving/Opportunity Factor
10.4.1.2. XX Driving/Opportunity Factor
10.5. North America Retinal Disorder Treatment Market Size and Forecast By Patient Demographics
10.5.1.1. XX Driving/Opportunity Factor
10.5.1.2. XX Driving/Opportunity Factor
10.6. North America Retinal Disorder Treatment Market Size and Forecast By End-User
10.6.1.1. XX Driving/Opportunity Factor
10.6.1.2. XX Driving/Opportunity Factor
10.7. North America Retinal Disorder Treatment Market Size and Forecast By Distribution Channel
10.7.1.1. XX Driving/Opportunity Factor
10.7.1.2. XX Driving/Opportunity Factor
10.8. U.S. Retinal Disorder Treatment Market
10.8.1.1. XX Driving/Opportunity Factor
10.8.1.2. XX Driving/Opportunity Factor
10.9. Canada Retinal Disorder Treatment Market
10.9.1.1. XX Driving/Opportunity Factor
10.9.1.2. XX Driving/Opportunity Factor
11. Europe Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Europe Retinal Disorder Treatment Market Size and Forecast By Disease Indication
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. Europe Retinal Disorder Treatment Market Size and Forecast By Dosage Form
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. Europe Retinal Disorder Treatment Market Size and Forecast By Patient Demographics
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. Europe Retinal Disorder Treatment Market Size and Forecast By Therapeutic Class
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. Europe Retinal Disorder Treatment Market Size and Forecast By End-User
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. Europe Retinal Disorder Treatment Market Size and Forecast By Distribution Channel
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. UK Retinal Disorder Treatment Market
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. Germany Retinal Disorder Treatment Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. France Retinal Disorder Treatment Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
11.11. Rest of Europe Retinal Disorder Treatment Market
11.11.1.1. XX Driving/Opportunity Factor
11.11.1.2. XX Driving/Opportunity Factor
12. Asia Pacific Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Asia-Pacific Retinal Disorder Treatment Market Size and Forecast By Disease Indication
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Asia-Pacific Retinal Disorder Treatment Market Size and Forecast By Dosage Form
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Asia-Pacific Retinal Disorder Treatment Market Size and Forecast By Patient Demographics
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Asia-Pacific Retinal Disorder Treatment Market Size and Forecast By Therapeutic Class
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Asia-Pacific Retinal Disorder Treatment Market Size and Forecast By End-User
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Asia-Pacific Retinal Disorder Treatment Market Size and Forecast By Distribution Channel
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. China Retinal Disorder Treatment Market
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. India Retinal Disorder Treatment Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Japan Retinal Disorder Treatment Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. Rest of Asia Pacific Retinal Disorder Treatment Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
13. Latin America Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Latin America Retinal Disorder Treatment Market Size and Forecast By Disease Indication
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Latin America Retinal Disorder Treatment Market Size and Forecast By Dosage Form
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Latin America Retinal Disorder Treatment Market Size and Forecast By Patient Demographics
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Latin America Retinal Disorder Treatment Market Size and Forecast By Therapeutic Class
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Latin America Retinal Disorder Treatment Market Size and Forecast By End-User
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Latin America Retinal Disorder Treatment Market Size and Forecast By Distribution Channel
13.8. Brazil Retinal Disorder Treatment Market
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Mexico Retinal Disorder Treatment Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. Rest of Latin America Retinal Disorder Treatment Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
14. MEA Retinal Disorder Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. MEA Retinal Disorder Treatment Market Size and Forecast By Disease Indication
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. MEA Retinal Disorder Treatment Market Size and Forecast By Dosage Form
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. MEA Retinal Disorder Treatment Market Size and Forecast By Patient Demographics
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. MEA Retinal Disorder Treatment Market Size and Forecast By Therapeutic Class
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. MEA Retinal Disorder Treatment Market Size and Forecast By End-User
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. MEA Retinal Disorder Treatment Market Size and Forecast By Distribution Channel
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. GCC Retinal Disorder Treatment Market
14.8.1.1. XX Driving/Opportunity Factor
14.8.1.2. XX Driving/Opportunity Factor
14.9. South Africa Retinal Disorder Treatment Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Rest of MEA Retinal Disorder Treatment Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
15. Companies in the Retinal Disorder Treatment Market
15.1. Santen Pharmaceutical Co., Ltd.
15.1.1. Company Snapshot
15.1.2. Company Overview
15.1.3. Financial Performance (2015-2019)
15.1.3.1. Net Revenue
15.1.3.2. Gross Profit
15.1.3.3. Geographical Revenue, 2019
15.1.4. Product Offerings
15.1.5. Recent Initiatives (2017-2019)
15.2. Regeneron Pharmaceuticals, Inc.
15.2.1. Company Snapshot
15.2.2. Company Overview
15.2.3. Financial Performance (2015-2019)
15.2.3.1. Net Revenue
15.2.3.2. Gross Profit
15.2.3.3. Geographical Revenue, 2019
15.2.4. Product Offerings
15.2.5. Recent Initiatives (2017-2019)
15.3. F. Hoffmann-La Roche Ltd.
15.3.1. Company Snapshot
15.3.2. Company Overview
15.3.3. Financial Performance (2015-2019)
15.3.3.1. Net Revenue
15.3.3.2. Gross Profit
15.3.3.3. Geographical Revenue, 2019
15.3.4. Product Offerings
15.3.5. Recent Initiatives (2017-2019)
15.4. Pfizer, Inc.
15.4.1. Company Snapshot
15.4.2. Company Overview
15.4.3. Financial Performance (2015-2019)
15.4.3.1. Net Revenue
15.4.3.2. Gross Profit
15.4.3.3. Geographical Revenue, 2019
15.4.4. Product Offerings
15.4.5. Recent Initiatives (2017-2019)
15.5. ALLERGAN PLC
15.5.1. Company Snapshot
15.5.2. Company Overview
15.5.3. Financial Performance (2015-2019)
15.5.3.1. Net Revenue
15.5.3.2. Gross Profit
15.5.3.3. Geographical Revenue, 2019
15.5.4. Product Offerings
15.5.5. Recent Initiatives (2017-2019)
15.6. Shire (Takeda Pharmaceutical Company Limited)
15.6.1. Company Snapshot
15.6.2. Company Overview
15.6.3. Financial Performance (2015-2019)
15.6.3.1. Net Revenue
15.6.3.2. Gross Profit
15.6.3.3. Geographical Revenue, 2019
15.6.4. Product Offerings
15.6.5. Recent Initiatives (2017-2019)
15.7. Bayer AG
15.7.1. Company Snapshot
15.7.2. Company Overview
15.7.3. Financial Performance (2015-2019)
15.7.3.1. Net Revenue
15.7.3.2. Gross Profit
15.7.3.3. Geographical Revenue, 2019
15.7.4. Product Offerings
15.7.5. Recent Initiatives (2017-2019)
15.8. Graybug Vision, Inc.
15.8.1. Company Snapshot
15.8.2. Company Overview
15.8.3. Financial Performance (2015-2019)
15.8.3.1. Net Revenue
15.8.3.2. Gross Profit
15.8.3.3. Geographical Revenue, 2019
15.8.4. Product Offerings
15.8.5. Recent Initiatives (2017-2019)
15.9. Novartis AG
15.9.1. Company Snapshot
15.9.2. Company Overview
15.9.3. Financial Performance (2015-2019)
15.9.3.1. Net Revenue
15.9.3.2. Gross Profit
15.9.3.3. Geographical Revenue, 2019
15.9.4. Product Offerings
15.9.5. Recent Initiatives (2017-2019)
15.10. Acucela Inc. (Kubota Pharmaceutical Holdings Co., Ltd.).
15.10.1. Company Snapshot
15.10.2. Company Overview
15.10.3. Financial Performance (2015-2019)
15.10.3.1. Net Revenue
15.10.3.2. Gross Profit
15.10.3.3. Geographical Revenue, 2019
15.10.4. Product Offerings
15.10.5. Recent Initiatives (2017-2019)
15.11. Other Notable Players
16. Conclusion
17. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Retinal Disorder Treatment Market Drivers & Restraints 2021
Table 7. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 198. Europe Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. Europe Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. Europe Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. Europe Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 242. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 243. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 244. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 245. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 246. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 247. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 248. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 249. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 250. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 251. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 252. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 253. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 254. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 255. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 256. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 257. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 258. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 259. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 260. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 261. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 262. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 367. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 368. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 369. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 370. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 371. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 372. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 373. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 374. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 375. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 376. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 377. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 378. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 379. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 380. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 381. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 382. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 383. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 384. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 385. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 386. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 387. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 388. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 389. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 390. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 391. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 392. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 393. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 394. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 395. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 396. Leading 10 Retinal Disorder Treatment Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 397. Santen Pharmaceutical Co., Ltd.Profile 2019 (CEO, HQ, Founded, Website)
Table 398. Santen Pharmaceutical Co., Ltd. Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 399. Regeneron Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 400. Regeneron Pharmaceuticals, Inc. Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 401. F. Hoffmann-La Roche Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 402. F. Hoffmann-La Roche Ltd..Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 403. Pfizer, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 404. Pfizer, Inc. Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 405. ALLERGAN PLC Profile 2019 (CEO, HQ, Founded, Website)
Table 406. ALLERGAN PLC Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 407. Shire (Takeda Pharmaceutical Company Limited) Profile 2019 (CEO, HQ, Founded, Website)
Table 408. Shire (Takeda Pharmaceutical Company Limited) Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 409. Bayer AG Profile 2019 (CEO, HQ, Founded, Website)
Table 410. Bayer AG Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 411. Graybug Vision, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 412. Graybug Vision, Inc. Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 413. Novartis AG Profile 2019 (CEO, HQ, Founded, Website)
Table 414. Novartis AG Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 415. Acucela Inc. (Kubota Pharmaceutical Holdings Co., Ltd.). Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 416. Acucela Inc. (Kubota Pharmaceutical Holdings Co., Ltd.). Retinal Disorder Treatment Product Offering (Segment, Product Offerings)
Table 417. Other Companies Involved in the Retinal Disorder Treatment Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Retinal Disorder Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Retinal Disorder Treatment Market Drivers & Restraints 2021
Figure 7. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Macular Degeneration Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Diabetic Retinopathy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Diabetic Macular Edema Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Retinal Vein Occlusion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Gels Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Eye Solutions Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Eye Drops Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Ointments Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Anti-VEGF Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Anti-inflammatory Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 153. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. North America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 158. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. North America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 163. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. North America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 168. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. North America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 173. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. North America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. North America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 183. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. North America Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 188. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. US Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. Canada Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 198. Europe Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. Europe Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. Europe Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. Europe Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 203. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. Europe Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. Europe Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. Europe Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 218. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. Europe Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 223. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. Europe Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 228. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 229. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 230. Europe Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 231. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 232. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 233. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 234. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 235. UK Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 236. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 237. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 238. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 239. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 240. Germany Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 241. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 242. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 243. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 244. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 245. France Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 246. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 247. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 248. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 249. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 250. Rest of Europe Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 251. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 252. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 253. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 254. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 255. Asia Pacific Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 256. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 257. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 258. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 259. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 260. Asia Pacific Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 261. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 262. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. Asia Pacific Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. Asia Pacific Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Asia Pacific Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. Asia Pacific Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Asia Pacific Retinal Disorder Treatment Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. China Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. India Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Japan Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. RoAPAC Retinal Disorder Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Middle East Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Middle East Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Middle East Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Middle East Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Middle East Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. Middle East Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Latin America Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. Latin America Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. Latin America Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. Latin America Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. Latin America Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. Latin America Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 367. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 368. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 369. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 370. Africa Retinal Disorder Treatment Market Forecast By Disease Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 371. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 372. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 373. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 374. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 375. Africa Retinal Disorder Treatment Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 376. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 377. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 378. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 379. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 380. Africa Retinal Disorder Treatment Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 381. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 382. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 383. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 384. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 385. Africa Retinal Disorder Treatment Market Forecast By Therapeutic Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 386. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 387. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 388. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 389. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 390. Africa Retinal Disorder Treatment Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 391. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 392. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 393. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 394. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 395. Africa Retinal Disorder Treatment Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 396. Porter’s Five Force Analysis
Companies Mentioned
1. GlaxoSmithKline PLC
2. Biomarin Pharmaceutical Inc
3. Grifols SA
4. UCB SA
5. Eisai Co Ltd
6. Novo Nordisk A/S
7. Alexion Pharmaceuticals Inc
8. Takeda Pharmaceutical Co Ltd
9. Chugai Pharmaceutical Co Ltd
10. Perrigo Company PLC
11. Astellas Pharma Inc
12. Mitsubishi Tanabe Pharma Corp
13. Johnson & Johnson
14. Shanghai Fosun Pharmaceutical Group Co Ltd
15. Jiangsu Hengrui Medicine Co Ltd
16. Allergan plc
17. Shire PLC
18. Kyowa Hakko Kirin Co Ltd
19. Pfizer Inc
20. Taisho Pharmaceutical Holdings Co Ltd
21. MYL.O
22. Zoetis Inc
23. Bristol-Myers Squibb Co
24. Merck & Co Inc
25. AbbVie Inc
26. Jazz Pharmaceuticals PLC
27. Sumitomo Dainippon Pharma Co Ltd
28. AstraZeneca PLC
29. China Grand Automotive Services Co Ltd
30. Daiichi Sankyo Co Ltd
31. Novartis AG
32. Tasly Pharmaceutical Group Co Ltd
33. CSL Ltd
34. Biogen Inc
35. Orion Oyj
36. Bayer AG
37. CSPC Pharmaceutical Group Ltd
38. Sanofi SA
39. Roche Holding AG
40. Ono Pharmaceutical Co Ltd
41. Beijing Tongrentang Co Ltd
42. Kangmei Pharmaceutical Co Ltd
43. Ipsen SA
44. Abbott Laboratories
45. Shionogi & Co Ltd
46. Eli Lilly and Co
47. Recordati Industria Chimica e Farmaceutica SpA
48. Hikma Pharmaceuticals PLC
49. Teva Pharmaceutical Industries Ltd
50. Merck KGaA
Companies Profiled in the Report
1. Santen Pharmaceutical Co., Ltd.
2. Regeneron Pharmaceuticals, Inc.
3. F. Hoffmann-La Roche Ltd.
4. Pfizer, Inc.
5. Allergan plc
6. Shire (Takeda Pharmaceutical Company Limited)
7. Bayer AG
8. Graybug Vision, Inc.
9. Novartis AG
10. Acucela Inc. (Kubota Pharmaceutical Holdings Co., Ltd.).
List of Companies Mentioned in the Report:
1. GlaxoSmithKline PLC
2. Biomarin Pharmaceutical Inc
3. Grifols SA
4. UCB SA
5. Eisai Co Ltd
6. Novo Nordisk A/S
7. Alexion Pharmaceuticals Inc
8. Takeda Pharmaceutical Co Ltd
9. Chugai Pharmaceutical Co Ltd
10. Perrigo Company PLC
11. Astellas Pharma Inc
12. Mitsubishi Tanabe Pharma Corp
13. Johnson & Johnson
14. Shanghai Fosun Pharmaceutical Group Co Ltd
15. Jiangsu Hengrui Medicine Co Ltd
16. Allergan plc
17. Shire PLC
18. Kyowa Hakko Kirin Co Ltd
19. Pfizer Inc
20. Taisho Pharmaceutical Holdings Co Ltd
21. MYL.O
22. Zoetis Inc
23. Bristol-Myers Squibb Co
24. Merck & Co Inc
25. AbbVie Inc
26. Jazz Pharmaceuticals PLC
27. Sumitomo Dainippon Pharma Co Ltd
28. AstraZeneca PLC
29. China Grand Automotive Services Co Ltd
30. Daiichi Sankyo Co Ltd
31. Novartis AG
32. Tasly Pharmaceutical Group Co Ltd
33. CSL Ltd
34. Biogen Inc
35. Orion Oyj
36. Bayer AG
37. CSPC Pharmaceutical Group Ltd
38. Sanofi SA
39. Roche Holding AG
40. Ono Pharmaceutical Co Ltd
41. Beijing Tongrentang Co Ltd
42. Kangmei Pharmaceutical Co Ltd
43. Ipsen SA
44. Abbott Laboratories
45. Shionogi & Co Ltd
46. Eli Lilly and Co
47. Recordati Industria Chimica e Farmaceutica SpA
48. Hikma Pharmaceuticals PLC
49. Teva Pharmaceutical Industries Ltd
50. Merck KGaA
List of Organizations Mentioned in the Report:
1. Centre for Pharmaceutical Administration Health Sciences Authority
2. Central Drug Standard Control Organization (CDSCO)
3. Organisation for Economic Co-operation and Development (OECD)
4. European Medicines Agency (EMA)
5. Food and Drug Administration (FDA)
6. National Institutes of Health (NIH)
7. United Nations (UN)
8. United Nations Office on Drugs and Crime (UNODC)
9. United Nations Statistics Division (UNSD)
10. Statistical Office of the European Union (EUROSTAT)
11. University of Connecticut
12. World Health Organization (WHO)
13. The National Medical Products Administration (NMPA)
14. Indian Council of Medical Research (ICMR)
15. The Therapeutic Goods Administration
16. The Federal Institute for Drugs and Medical Devices (BfArM)
17. Pharmaceuticals and Medical Devices Agency (PMDA)
18. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
19. Ministry of Health, Labour & Welfare(MHLW)
20. Medicines and Healthcare Products Regulatory Agency (MHRA)
1. Santen Pharmaceutical Co., Ltd.
2. Regeneron Pharmaceuticals, Inc.
3. F. Hoffmann-La Roche Ltd.
4. Pfizer, Inc.
5. Allergan plc
6. Shire (Takeda Pharmaceutical Company Limited)
7. Bayer AG
8. Graybug Vision, Inc.
9. Novartis AG
10. Acucela Inc. (Kubota Pharmaceutical Holdings Co., Ltd.).
List of Companies Mentioned in the Report:
1. GlaxoSmithKline PLC
2. Biomarin Pharmaceutical Inc
3. Grifols SA
4. UCB SA
5. Eisai Co Ltd
6. Novo Nordisk A/S
7. Alexion Pharmaceuticals Inc
8. Takeda Pharmaceutical Co Ltd
9. Chugai Pharmaceutical Co Ltd
10. Perrigo Company PLC
11. Astellas Pharma Inc
12. Mitsubishi Tanabe Pharma Corp
13. Johnson & Johnson
14. Shanghai Fosun Pharmaceutical Group Co Ltd
15. Jiangsu Hengrui Medicine Co Ltd
16. Allergan plc
17. Shire PLC
18. Kyowa Hakko Kirin Co Ltd
19. Pfizer Inc
20. Taisho Pharmaceutical Holdings Co Ltd
21. MYL.O
22. Zoetis Inc
23. Bristol-Myers Squibb Co
24. Merck & Co Inc
25. AbbVie Inc
26. Jazz Pharmaceuticals PLC
27. Sumitomo Dainippon Pharma Co Ltd
28. AstraZeneca PLC
29. China Grand Automotive Services Co Ltd
30. Daiichi Sankyo Co Ltd
31. Novartis AG
32. Tasly Pharmaceutical Group Co Ltd
33. CSL Ltd
34. Biogen Inc
35. Orion Oyj
36. Bayer AG
37. CSPC Pharmaceutical Group Ltd
38. Sanofi SA
39. Roche Holding AG
40. Ono Pharmaceutical Co Ltd
41. Beijing Tongrentang Co Ltd
42. Kangmei Pharmaceutical Co Ltd
43. Ipsen SA
44. Abbott Laboratories
45. Shionogi & Co Ltd
46. Eli Lilly and Co
47. Recordati Industria Chimica e Farmaceutica SpA
48. Hikma Pharmaceuticals PLC
49. Teva Pharmaceutical Industries Ltd
50. Merck KGaA
List of Organizations Mentioned in the Report:
1. Centre for Pharmaceutical Administration Health Sciences Authority
2. Central Drug Standard Control Organization (CDSCO)
3. Organisation for Economic Co-operation and Development (OECD)
4. European Medicines Agency (EMA)
5. Food and Drug Administration (FDA)
6. National Institutes of Health (NIH)
7. United Nations (UN)
8. United Nations Office on Drugs and Crime (UNODC)
9. United Nations Statistics Division (UNSD)
10. Statistical Office of the European Union (EUROSTAT)
11. University of Connecticut
12. World Health Organization (WHO)
13. The National Medical Products Administration (NMPA)
14. Indian Council of Medical Research (ICMR)
15. The Therapeutic Goods Administration
16. The Federal Institute for Drugs and Medical Devices (BfArM)
17. Pharmaceuticals and Medical Devices Agency (PMDA)
18. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
19. Ministry of Health, Labour & Welfare(MHLW)
20. Medicines and Healthcare Products Regulatory Agency (MHRA)
Download sample pages
Complete the form below to download your free sample pages for Retinal Disorder Treatment Market Report 2021-2031Download sample pages
Complete the form below to download your free sample pages for Retinal Disorder Treatment Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Bioreactors Market Report 2023-2033
The global Bioreactors market was estimated to be valued at US$ 9,9770.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.
29 September 2023
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
27 September 2023
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
25 September 2023
Visiongain Publishes Anti-infective Vaccines Market Report 2023-2033
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
21 September 2023
